2,400
Views
0
CrossRef citations to date
0
Altmetric
Pharmacology

Network pharmacology-based approach to research the effect and mechanism of Si-Miao-Yong-An decoction against thromboangiitis obliterans

, , , , , & show all
Article: 2218105 | Received 20 Dec 2022, Accepted 20 May 2023, Published online: 15 Jun 2023

References

  • Olin JW, Shih A. Thromboangiitis obliterans (Buerger’s disease). Curr Opin Rheumatol. 2006;18(1):1–15.
  • Li HY, Sun H, Zhang AH, et al. Therapeutic effect and mechanism of Si-Miao-Yong-an-Tang on thromboangiitis obliterans based on the urine metabolomics approach. Front Pharmacol. 2022;13:827733.
  • Małecki R, Zdrojowy K, Adamiec R. Thromboangiitis obliterans in the 21st century—a new face of disease. Atherosclerosis. 2009;206(2):328–334.
  • Li MD, Wang YF, Yang MW, et al. Risk factors, mechanisms and treatments of thromboangiitis obliterans: an overview of recent research. Curr Med Chem. 2020;27(35):6057–6072.
  • Modaghegh MS, Hafezi S. Endovascular treatment of thromboangiitis obliterans (Buerger’s disease). Vasc Endovascular Surg. 2018;52(2):124–130.
  • Norona LM, Fullerton A, Lawson C, et al. In vitro assessment of farnesoid X receptor antagonism to predict drug-induced liver injury risk. Arch Toxicol. 2020;94(9):3185–3200.
  • Li G, Zefr C, Yang B, et al. Herbal therapy treatment in thromboangiitis obliterans: a retrospective clinical study. Ann Palliat Med. 2020;9(4):1696–1707.
  • Du A, Xie Y, Ouyang H, et al. Si-Miao-Yong-An decoction for diabetic retinopathy: a combined network pharmacological and in vivo approach. Front Pharmacol. 2021;12:763163.
  • Liu C. The efficacy of Si Miao Yong An Tang in the treatment of vaso-occlusive vasculitis. J Appropriate Clin Med. 2018;11(19):2.
  • Chen C. Guidelines for diagnosis and treatment of common syndromes in peripheral vascular department (2015). Hebei Med J. 2016;1:151–154.
  • Wang X, Wang ZY, Zheng JH, et al. TCM network pharmacology: a new trend towards combining computational, experimental and clinical approaches. Chin J Nat Med. 2021;19(1):1–11.
  • Ru J, Li P, Wang J, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminform. 2014;6:13.
  • Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46(D1):D1074–D1082.
  • Stelzer G, Rosen N, Plaschkes I, et al. The GeneCards suite: from gene data mining to disease genome sequence analyses. Curr Protoc Bioinformatics. 2016;54:1.30.1–1.30.33.
  • Otasek D, Morris JH, Bouças J, et al. Cytoscape automation: empowering workflow-based network analysis. Genome Biol. 2019;20(1):185.
  • Ashida S, Ishihara M, Ogawa H, et al. Protective effect of ticlopidine on experimentally induced peripheral arterial occlusive disease in rats. Thromb Res. 1980;18(1–2):55–67.
  • Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7(2):27–31.
  • Sies H. Oxidative stress: a concept in redox biology and medicine. Redox Biol. 2015;4:180–183.
  • Sharebiani H, Fazeli B, Maniscalco R, et al. The imbalance among oxidative biomarkers and antioxidant defense systems in thromboangiitis obliterans (Winiwarter-Buerger disease). J Clin Med. 2020;9(4):1036.
  • Du YM, Du BH, Yang J, et al. Effect of Bradykinin on rats with thromboangiitis obliterans through PI3K/Akt signaling pathway. Eur Rev Med Pharmacol Sci. 2019;23(22):10169–10176.
  • Fazeli B, Keramat S, Assadi L, et al. Angiogenesis induction in Buerger’s disease: a disease management double-edged sword? Orphanet J Rare Dis. 2019;14(1):189.
  • Zheng X, Liu H, Ma M, et al. Anti-thrombotic activity of phenolic acids obtained from Salvia miltiorrhiza f. alba in TNF-α-stimulated endothelial cells via the NF-κB/JNK/p38 MAPK signaling pathway. Arch Pharm Res. 2021;44(4):427–438.
  • Keramat S, Sadeghian MH, Keramati MR, et al. Assessment of T helper 17-associated cytokines in thromboangiitis obliterans. J Inflamm Res. 2019;12:251–258.
  • Wang S, Hu Y, Tan W, et al. Compatibility art of traditional Chinese medicine: from the perspective of herb pairs. J Ethnopharmacol. 2012;143(2):412–423.
  • Shen P, Lin W, Deng X, et al. Potential implications of quercetin in autoimmune diseases. Front Immunol. 2021;12:689044.
  • Choi S, Kim KW, Choi JS, et al. Angiogenic activity of beta-sitosterol in the ischaemia/reperfusion-damaged brain of Mongolian gerbil. Planta Med. 2002;68(4):330–335.
  • Franchin M, Cólon DF, Castanheira FV, et al. Vestitol isolated from Brazilian red propolis inhibits neutrophils migration in the inflammatory process: elucidation of the mechanism of action. J Nat Prod. 2016;79(4):954–960.
  • Loizou S, Lekakis I, Chrousos GP, et al. Beta-sitosterol exhibits anti-inflammatory activity in human aortic endothelial cells. Mol Nutr Food Res. 2010;54(4):551–558.
  • Dellalibera-Joviliano R, Joviliano EE, Silva JS, et al. Activation of cytokines corroborate with development of inflammation and autoimmunity in thromboangiitis obliterans patients. Clin Exp Immunol. 2012;170(1):28–35.
  • Annex BH, Cooke JP. New directions in therapeutic angiogenesis and arteriogenesis in peripheral arterial disease. Circ Res. 2021;128(12):1944–1957.
  • Hewing B, Stangl V, Stangl K, et al. Circulating angiogenic factors in patients with thromboangiitis obliterans. PLOS One. 2012;7(4):e34717.
  • Isner JM, Baumgartner I, Rauh G, et al. Treatment of thromboangiitis obliterans (Buerger’s disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. J Vasc Surg. 1998;28(6):964–973, discussion 73–75.
  • Zhou H, Li CL, Xia PZ, et al. MiR-223 alleviates thrombus and inflammation in thromboangiitis obliterans rats by regulating NLRP3. Eur Rev Med Pharmacol Sci. 2020;24(20):10605–10611.
  • Dellalibera-Joviliano R, Jacob-Ferreira AL, Joviliano EE, et al. Imbalanced matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 activities in patients with thromboangiitis obliterans. Vasc Med. 2012;17(2):73–78.
  • Fei J, Liang B, Jiang C, et al. Luteolin inhibits IL-1β-induced inflammation in rat chondrocytes and attenuates osteoarthritis progression in a rat model. Biomed Pharmacother. 2019;109:1586–1592.
  • Tang J, Diao P, Shu X, et al. Quercetin and quercitrin attenuates the inflammatory response and oxidative stress in LPS-Induced RAW264.7 cells: in vitro assessment and a theoretical model. Biomed Res Int. 2019;2019:7039802.
  • Abdel-Hamed AR, Mehanna ET, Hazem RM, et al. Plicosepalus acacia extract and its major constituents, methyl gallate and quercetin, potentiate therapeutic angiogenesis in diabetic hind limb ischemia: HPTLC quantification and LC–MS/MS metabolic profiling. Antioxidants. 2021;10(11):1701.
  • Hu WH, Wang HY, Xia YT, et al. Kaempferol, a major flavonoid in Ginkgo folium, potentiates angiogenic functions in cultured endothelial cells by binding to vascular endothelial growth factor. Front Pharmacol. 2020;11:526.
  • Moon EJ, Lee YM, Lee OH, et al. A novel angiogenic factor derived from Aloe vera gel: beta-sitosterol, a plant sterol. Angiogenesis. 1999;3(2):117–123.